Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: A prospective, real-life, observational study

Table 2 Treatment planned and actually received (n = 674): Univariate analysis

	Therapeutic education
	No (n = 304)	Yes (n = 370)	P
Duration of bitherapy (wk)1
Planned	27.7 ± 8.9	27.1 ± 8.2	0.49
Actual	28.4 ± 12.7	30.3 ± 14.2	0.25
Premature discontinuation (< 20 wk)	44/304 (15)	41/370 (11)	0.20
Peginterferon weekly dose (μg/kg)
Planned	1.35 ± 0.29	1.41 ± 0.22	0.01
Actual at 3 mo2	1.31 ± 0.30	1.38 ± 0.25	0.006
Actual at 6 mo2	1.18 ± 0.35	1.25 ± 0.31	0.02
Ribavirin daily dose (mg)
Planned	897 ± 147	906 ± 154	0.67
Actual at 3 mo2	871 ± 166	885 ± 175	0.25
Actual at 6 mo2	771 ± 201	803 ± 209	0.06

Data are expressed as mean ± SD, or proportions of patients.

¹Date of end of bitherapy minus date of inclusion;

²Cumulated over the past 3 mo (AUC, investigator report).